Multifocal High ADD Contact Lens Proof of Concept Trial
Launched by ALCON RESEARCH · Apr 16, 2014
Trial Information
Current as of August 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must sign an Informed Consent document;
- • Presbyopic and require at least 2.25 diopters (D) spectacle ADD power;
- • Current or previous soft contact lens wearer;
- • Not able to achieve monocular near visual acuity (VA) 0.2 logarithm of the Minimum Angle of Resolution (logMAR) \[Early Treatment of Diabetic Retinopathy Study (ETDRS)\] or better in each eye with AIR OPTIX® AQUA Multifocal (AOAMF) High ADD Contact Lenses;
- • Willing and able to wear multifocal contact lenses in both eyes within the available range of powers for this trial;
- • Manifest cylinder less than or equal to 1.00 D;
- • Able to achieve best corrected visual acuity (BCVA) of 20/25 or better in each eye at distance (as determined by manifest refraction);
- • Other protocol-defined inclusion criteria may apply.
- Exclusion Criteria:
- • Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment, as determined by the investigator;
- • Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator; or any use of topical ocular medications that would require instillation during contact lens wear;
- • Any history of herpetic keratitis;
- • History of corneal or refractive surgery, irregular cornea or unilateral pseudophakia;
- • Biomicroscopy findings (except for corneal vascularization) that are moderate (Grade 3) or severe (Grade 4);
- • Corneal vascularization that is mild (Grade 2) or higher;
- • A pathologically dry eye that precludes contact lens wear;
- • Monocular (only 1 eye with functional vision);
- • Anisometropia ≥ 1.50 D (contact lens distance prescription);
- • Clinically significant (\> 1 millimeter) anisocoria;
- • History of intolerance or hypersensitivity to any component of the investigational products;
- • Concurrent participation in a contact lens or contact lens care product clinical trial within the previous 30 days;
- • Eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment;
- • Any ocular or systemic medical condition that may, in the opinion of the Investigator, preclude safe administration of the study lenses or affect the results of this study;
- • Other protocol-defined exclusion criteria may apply.
About Alcon Research
Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Sr. Clinical Manager, Vision Care, GCRA
Study Director
Alcon Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials